Q-omics provides the consensus-scored SAMD7 profile across patient tissues and cancer cell-line models. SAMD7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SAMD7 is differentially expressed in 7, with the highest sampling consensus in READ. Additionally, SAMD7 RNA expression shows 6,614 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, READ, and STAD as cancer lineages where SAMD7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SAMD7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SAMD7 survival associations across molecular data types. SAMD7 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SAMD7 RNA expression–survival associations across cancer types. High SAMD7 expression shows unfavorable associations in KICH, ACC, KIRC, UVM, READ and UCEC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SAMD7 RNA expression.
This table summarizes SAMD7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in READ for RNA.
This table ranks reproducible tumor–normal expression differences for SAMD7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SAMD7 shows lower tumor expression in READ and THCA and higher tumor expression in COAD, UCEC, BLCA and KIRP. The READ box plot shows higher SAMD7 RNA expression in normal versus tumor tissue (log2 FC = −0.035, t-test p = .019).
This table shows molecular features associated with SAMD7 in patient tissues and cancer cell lines. In patient samples, SAMD7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SAMD7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
